1. Signaling Pathways
  2. GPCR/G Protein
  3. PACAP Receptor
  4. VPAC2 receptor Isoform

VPAC2 receptor

Pituitary adenylyl cyclase-activating polypeptide receptor VPAC2 (VIPR2) is a class B G protein-coupled receptor that binds both vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) with high affinity and primarily activates adenylyl cyclase-dependent signaling pathways[1][2]. VPAC2 participates in neuroendocrine regulation, circadian rhythm synchronization, immune modulation, and metabolic control through cAMP-mediated intracellular signaling cascades[1][3]. Mechanistically, VPAC2 belongs to the PACAP/VIP receptor family together with VPAC1 and PAC1; however, unlike PAC1, which displays marked preference for PACAP, VPAC2 recognizes VIP and PACAP with comparable affinity, providing a distinct signaling profile and physiological function[2][4]. In experimental systems, VPAC2 signaling has been implicated in central nervous system development and neuroprotection, and VPAC2 receptor activation mediates VIP-induced protection against neonatal excitotoxic brain injury in mice[5]. Genetic and pharmacological studies further associate VPAC2-regulated signaling with circadian clock function and neuropsychiatric phenotypes, supporting its relevance in neurological disease models[3][6]. Beyond the nervous system, VPAC2 is expressed in pancreatic islets and contributes to peptide-mediated regulation of insulin and glucagon secretion, linking receptor activity to metabolic homeostasis[7]. For experimental applications, selective VPAC2 agonists have been developed and are widely used to investigate receptor-specific signaling, cellular responses, and therapeutic potential within the VIP/PACAP receptor network[8].

VPAC2 receptor Related Products (2):

Cat. No. Product Name Effect Purity
  • HY-P10768A
    Ro 25-1553 TFA
    Agonist
    Ro 25-1553 TFA is a 31 amino acid vasoactive intestinal peptide (VIP) analog, that acts as an agonist for VIP2 receptor (VPAC2 receptor). Ro 25-1553 TFA exhibits a bronchodilator effect in nerve-induced or Carbachol (HY-B1208)-induced tracheal smooth muscle contraction in guinea pig model.
  • HY-P10768
    Ro 25-1553
    Agonist
    Ro 25-1553 is a selective VIP2 receptor (VPAC2 receptor) agonist. Ro 25-1553 exhibits bronchodilatory effects on tracheal smooth muscle contractions induced by nerve stimulation or Carbachol (HY-B1208). Ro 25-1553 produces a superimposed effect when combined with Formoterol and Salmeterol (HY-14302). Ro 25-1553 can be used for the study of bronchoconstriction.